Skip to main content

Table 3 In vitro antifungal susceptibilities of 43 clinical C. africana isolates as determined by the Clinical and Laboratory Standards Institute (CLSI) method

From: Multilocus sequence typing analysis of Candida africana from vulvovaginal candidiasis

Candida species   BUC CLO FLC ITC MIC TEC VRC
C. africana
DST 182
(14)
Range
GM
MIC90
0.030–1.00
0.096
0.500
0.030–1.00
0.044
0.030
0.125–2.00
0.540
2.000
0.030–0.03
0.030
0.030
0.015–0.50
0.083
0.500
0.030–0.50
0.047
0.060
0.030–0.25
0.037
0.030
C. africana
DST 782
(22)
Range
GM
MIC90
0.015–0.25
0.037
0.125
0.03–0.125
0.032
0.030
0.250–2.00
0.484
1.000
0.015–0.03
0.027
0.030
0.015–0.25
0.024
0.030
0.03–0.125
0.051
0.125
0.030–0.06
0.030
0.030
C. africana
DST 3142
(7)
Range
GM
MIC90
0.030–0.50
0.060
0.250
0.030–0.03
0.030
0.030
0.250–0.50
0.410
0.500
0.030–0.03
0.030
0.030
0.015–0.50
0.045
0.500
0.03–0.125
0.044
0.060
0.03–0.125
0.036
0.030
Sub-total
(43)
Range
GM
MIC90
0.015–1.00
0.051
0.250
0.030–1.00
0.034
0.030
0.125–2.00
0.482
1.000
0.015–0.03
0.028
0.030
0.015–0.50
0.036
0.500
0.030–0.50
0.049
0.125
0.030–0.25
0.033
0.030
C. albicans ATCC90028
(5)
Range
GM
MIC90
0.03–0.125
0.039
0.125
0.030–0.06
0.034
0.060
0.500–1.00
0.757
1.000
0.030–0.06
0.052
0.060
0.030–0.50
0.060
0.500
0.030
0.030
0.030
0.030
0.030
0.030
  1. BUC butoconazole, CLO Clotrimazole, FLC Fluconazole, ITC Itraconazole, VRC Voriconazole, MIC Miconazole, TEC Terconazole